Several other equities research analysts have also recently commented on the company. Shore Capital restated a sell rating on shares of AstraZeneca plc in a research note on Wednesday, March 15th. Liberum Capital restated a buy rating and issued a GBX 5,100 ($62.99) target price on shares of AstraZeneca plc in a research note on Wednesday, March 15th. JPMorgan Chase & Co. restated a neutral rating on shares of AstraZeneca plc in a research note on Wednesday, March 15th. Deutsche Bank AG restated a buy rating and issued a GBX 5,500 ($67.93) target price on shares of AstraZeneca plc in a research note on Wednesday, March 15th. Finally, Jefferies Group LLC boosted their target price on AstraZeneca plc from GBX 5,250 ($64.84) to GBX 5,350 ($66.07) and gave the company a buy rating in a research note on Thursday, March 9th. Four analysts have rated the stock with a sell rating, eight have issued a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of Hold and an average target price of GBX 5,018.36 ($61.98).
AstraZeneca plc (LON:AZN) opened at 4871.50 on Thursday. The company’s market cap is GBX 61.64 billion. The stock’s 50 day moving average is GBX 4,617.49 and its 200 day moving average is GBX 4,602.58. AstraZeneca plc has a 52-week low of GBX 3,680.00 and a 52-week high of GBX 5,505.00.
var userip;Your IP Address: document.write(userip);
The company also recently disclosed a dividend, which was paid on Monday, March 20th. Shareholders of record on Thursday, February 16th were issued a GBX 150.20 ($1.86) dividend. This represents a yield of 3.52%. This is a positive change from AstraZeneca plc’s previous dividend of $68.70. The ex-dividend date of this dividend was Thursday, February 16th.
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.